Merck has entered into an agreement to acquire Rigontec, a biotechnology company developing cancer immunotherapies, for €115 million upfront and as much as €349 million in milestone payments. Rigontec’s lead candidate, RGT100, is currently in Phase I development for the treatment of various tumors. “Rigontec’s immuno-oncology approach of engaging the innate immune system to safely eliminate cancer cells complements our strategy and our current pipeline,” said Dr. Eric Rubin, vice president of...